AlphaCentric Funds > Mutual Fund Series Trust
AlphaCentric LifeSci Healthcare Fund
$99.33M
Avg Monthly Net Assets
$83.53M
Total Assets
$719K
Total Liabilities
$82.81M
Net Assets
AlphaCentric LifeSci Healthcare Fund is a Mutual Fund in Mutual Fund Series Trust
from AlphaCentric Funds,
based in Nebraska,
United States of America.
The fund has three share classes
and monthly net assets of $99.33M.
On August 28th, 2024 it reported 60 holdings, the largest
being United Therapeutics Corporation (5.6%), First American Funds Inc. (5.1%) and BioCryst Pharmaceuticals Inc. (5.0%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Ticker | Monthly Returns (2 years) |
|---|---|---|---|
| AlphaCentric LifeSci Healthcare Fund Class A | C000215731 | LYFAX | |
| AlphaCentric LifeSci Healthcare Fund Class C | C000215729 | LYFCX | |
| AlphaCentric LifeSci Healthcare Fund Class I | C000215730 | LYFIX |
Holdings
From latest NPORT-P, filed August 28th, 2024 for period ending June 30th, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| ACADIA PHARMACEU (Acadia Pharmaceuticals Inc) | Long | Equity-common | US | $2M | 100K | 1.96 |
| AMICUS THERAPEUT (Amicus Therapeutics Inc.) | Long | Equity-common | US | $2M | 203K | 2.43 |
| AMPHASTAR PHARMA (Amphastar Pharmaceuticals Inc) | Long | Equity-common | US | $1M | 25K | 1.21 |
| ARGENX SE - ADR | Long | Equity-common | NL | $3M | 7K | 3.76 |
| ARRIVENT BIOPHAR (ArriVent BioPharma Inc.) | Long | Equity-common | US | $2M | 86K | 1.93 |
| ASTELLAS PHARMA INC-UNSP (Astellas Pharma Inc.) | Long | Equity-common | JP | $838K | 85K | 1.01 |
| AURINIA PHARMACE (Aurinia Pharmaceuticals Inc) | Long | Equity-common | CA | $457K | 80K | 0.55 |
| AXSOME THERAPEUT (Axsome Therapeutics Inc.) | Long | Equity-common | US | $1M | 15K | 1.46 |
| BEIGENE LTD-ADR (BeiGene Ltd.) | Long | Equity-common | KY | $2M | 15K | 2.58 |
| BICYCLE THER-ADR (Bicycle Therapeutics PLC) | Long | Equity-common | GB | $1M | 60K | 1.47 |
| BIOCRYST PHARM (BioCryst Pharmaceuticals Inc.) | Long | Equity-common | US | $4M | 675K | 5.04 |
| BIOMARIN PHARMAC (Biomarin Pharmaceutical Inc.) | Long | Equity-common | US | $1M | 17K | 1.64 |
| CABALETTA BIO INC | Long | Equity-common | US | $524K | 70K | 0.63 |
| CELLDEX THERAPEU (Celldex Therapeutics Inc.) | Long | Equity-common | US | $2M | 48K | 2.12 |
| CEREVEL THERAPEU (Cerevel Therapeutics Holdings Inc) | Long | Equity-common | US | $2M | 43K | 2.10 |
| CG ONCOLOGY INC (CG Oncology Inc.) | Long | Equity-common | US | $32K | 1K | 0.04 |
| COHERUS BIOSCIEN (Coherus Biosciences Inc) | Long | Equity-common | US | $2M | 1M | 2.09 |
| DOCGO INC | Long | Equity-common | US | $2M | 650K | 2.43 |
| DYNAVAX TECHNOLO (Dynavax Technologies Corp.) | Long | Equity-common | US | $1M | 130K | 1.76 |
| DYNE THERAPEUTIC (Dyne Therapeutics Inc.) | Long | Equity-common | US | $706K | 20K | 0.85 |
| EMBECTA CORP (Embecta Corp.) | Long | Equity-common | US | $706K | 57K | 0.85 |
| ENOVIS CORP (Enovis Corporation) | Long | Equity-common | US | $904K | 20K | 1.09 |
| EXACT SCIENCES (Exact Sciences Corporation) | Long | Equity-common | US | $1M | 30K | 1.53 |
| FID-MM GOVT-I (Fidelity Institutional Cash Portfolios) | Long | Short-term investment vehicle | US | $1.43 | – | 0.00 |
| FIRST AM-TR OB-X (First American Funds Inc.) | Long | Short-term investment vehicle | US | $4M | – | 5.13 |
| GALAPAGOS NV-ADR | Long | Equity-common | BE | $3M | 109K | 3.25 |
| GILEAD SCIENCES (Gilead Sciences, Inc.) | Long | Equity-common | US | $240K | 4K | 0.29 |
| GSK PLC-ADR | Long | Equity-common | GB | $1M | 35K | 1.63 |
| HARMONY BIOSCIE (Harmony Biosciences Holdings Inc) | Long | Equity-common | US | $4M | 122K | 4.44 |
| IMMATICS NV (Immatics N.V) | Long | Equity-common | NL | $232K | 20K | 0.28 |
| IMMUNOVANT INC | Long | Equity-common | US | $964K | 37K | 1.16 |
| INARI MEDICAL IN (Inari Medical Inc) | Long | Equity-common | US | $722K | 15K | 0.87 |
| INTRA-CELLULAR T (Intra-Cellular Therapies Inc) | Long | Equity-common | US | $1M | 20K | 1.65 |
| JAZZ PHARMACEUTI (Jazz Pharmaceuticals PLC) | Long | Equity-common | IE | $1M | 11K | 1.42 |
| KALVISTA PHARMAC (KalVista Pharmaceuticals Inc.) | Long | Equity-common | US | $29K | 3K | 0.04 |
| KARYOPHARM THERA (Karyopharm Therapeutics Inc) | Long | Equity-common | US | $976K | 1M | 1.18 |
| MEDTRONIC PLC | Long | Equity-common | IE | $1M | 18K | 1.66 |
| MIRUM PHARMACEUT (Mirum Pharmaceuticals Inc.) | Long | Equity-common | US | $2M | 64K | 2.64 |
| NEUROCRINE BIOSC (Neurocrine Biosciences Inc) | Long | Equity-common | US | $964K | 7K | 1.16 |
| NUVATION BIO INC | Long | Equity-common | US | $394K | 135K | 0.48 |
| PACIRA BIOSCIENC (Pacira Biosciences Inc) | Long | Equity-common | US | $3M | 118K | 4.06 |
| PERSPECTIVE THER (Perspective Therapeutics Inc) | Long | Equity-common | US | $818K | 82K | 0.99 |
| PFIZER INC (Pfizer Inc.) | Long | Equity-common | US | $4M | 140K | 4.73 |
| PROTAGONIST THER (Protagonist Therapeutics Inc) | Long | Equity-common | US | $866K | 25K | 1.05 |
| REVANCE THERAPEU (Revance Therapeutics Inc) | Long | Equity-common | US | $630K | 245K | 0.76 |
| ROIVANT SCIENCES (Roivant Sciences Ltd) | Long | Equity-common | BM | $930K | 88K | 1.12 |
| ROYALTY PHARMA-A (Royalty Pharma PLC) | Long | Equity-common | GB | $2M | 60K | 1.91 |
| SAGIMET BIOSCI-A (Sagimet Biosciences Inc.) | Long | Equity-common | US | $633K | 185K | 0.76 |
| SANOFI-ADR | Long | Equity-common | FR | $849K | 18K | 1.03 |
| SAREPTA THERAPEU (Sarepta Therapeutics Inc) | Long | Equity-common | US | $1M | 8K | 1.43 |
| STRUCTURE THERAP (Structure Therapeutics Inc) | Long | Equity-common | KY | $1M | 26K | 1.23 |
| TOURMALINE BIO I (Tourmaline Bio Inc) | Long | Equity-common | US | $965K | 75K | 1.16 |
| UNIQURE NV (Uniqure N.V.) | Long | Equity-common | NL | $2M | 460K | 2.49 |
| UNITED THERAPEUT (United Therapeutics Corporation) | Long | Equity-common | US | $5M | 15K | 5.58 |
| VALNEVA SE - ADR | Long | Equity-common | FR | $649K | 88K | 0.78 |
| VENTYX BIOSCIENC (Ventyx Biosciences Inc.) | Long | Equity-common | US | $23K | 10K | 0.03 |
| VERONA PHAR-ADR (Verona Pharma Plc) | Long | Equity-common | GB | $810K | 56K | 0.98 |
| VIKING THERAPEUT (Viking Therapeutics Inc.) | Long | Equity-common | US | $875K | 17K | 1.06 |
| VIRIDIAN THERAPE (Viridian Therapeutics Inc) | Long | Equity-common | US | $163K | 13K | 0.20 |
| VYNE THERAPEUTIC (VYNE Therapeutics Inc) | Long | Equity-common | US | $612K | 311K | 0.74 |
Address
Mutual Fund Series Trust
4221 NORTH 203RD STREET, SUITE 100
Elkhorn
Nebraska
68022-3474
United States of America
Websites
Directors
Stephen P. Lachenauer
Tiberiu Weisz
Jerry Szilagyi
Tobias Caldwell
Transfer Agents
Ultimus Fund Solutions, LLC
Pricing Services
ICE Data Services
Custodians
U.S. Bank National Association
Shareholder Servicing Agents
Ultimus Fund Solutions, LLC
Admins
Ultimus Fund Solutions, LLC
Brokers
BTIG, LLC